Collaborations and partnerships
Alligator conducts its research and development of drug candidates both in its own R&D department and through partnerships with other organizations. We continuously strengthen our position by developing highly innovative and effective drug candidates. To do so, our ambition is to establish long-term strategic and value creating collaborations with the pharma and biotech industry as well as with academic institutions.
Alligator's strategy is to develop drug candidates to clinical phase II, but the company may consider outlicensing or co-development partnerships at an earlier phase as well. Partnerships in research or preclinical development projects may be in the form of inlicensing of immaterial rights or in the form of co-development of drug candidates where costs and future revenues are shared between the parties.
- In July 2017, an agreement was signed with the US biotechnology company Aptevo Therapeutics Inc., for co-development of the bispecific drug candidate ALG.APV-527. Under the terms of the agreement, the parties will jointly own and share equally the development costs associated with advancing this candidate through to the end of phase II clinical development.
- In August 2019, an agreement was concluded with Biotheus Inc. of China. Biotheus obtained the Chinese rights to an antibody from the ALLIGATOR-GOLD antibody library. The agreement gives Alligator the right to total initial upfront payments, and milestone and option payments of potentially USD 142 million.
- In April 2021, a joint research collaboration agreement was concluded with MacroGenics, Inc. The research collaboration will lead to the expansion of Alligator’s proprietary patient specific immunotherapy Neo-X-Prime™.
- In May 2021, a joint research agreement was signed with BioArctic AB, a Swedish research-based biopharma company. Under the agreement, Alligator will employ its proprietary antibody generation technologies in collaboration with BioArctic to develop new product candidates.
- Through its subsidiary Atlas Therapeutics AB, Alligator holds a participating interest in the clinical project Biosynergy (AC101/ HLX22), run by the Korean company AbClon. The drug candidate is now being further developed by the Chinese company Shanghai Henlius. Alligator incurs no overheads for this project but is entitled to 35% of AbClon’s proceeds from the outlicensing to Shanghai Henlius. AC101 is currently in clinical phase I development.
Alligator welcomes opportunities to collaborate with biotech companies as well as academic institutions, for joint development of novel, innovative immunotherapies. We encourage organizations wishing to discuss partnerships related to immaterial rights to novel targets or drug candidates to contact us at firstname.lastname@example.org